SYRS Live signals | Maximize Profits with Getagraph.com

SELL 105752 min ago

@ $7.03

Issued: 14 Feb 2024 @ 09:30

Return: -28.31%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 3.84 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines...

Stats
Today's Volume	44 487.00
Average Volume	209 833
Market Cap	134.71M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.890 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.870
ATR14	$0.0190 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Roth David	Sell	10 451	Common Stock
2024-03-31	Stephens Kristin	Buy	11 666	Common Stock
2024-04-01	Stephens Kristin	Sell	4 218	Common Stock
2024-03-31	Stephens Kristin	Sell	11 666	Restricted Stock Units
2024-03-31	Stephens Kristin	Buy	2 000	Common Stock

INSIDER POWER
54.83
Last 100 transactions
Buy: 2 824 203 \| Sell: 497 307

Volume Correlation

Long: 0.14 (neutral)

Short: -0.12 (neutral)

Signal:(42) Neutral

Syros Pharmaceuticals Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Syros Pharmaceuticals Inc Correlation - Currency/Commodity

0.31
( neutral )

0.35
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.27
( neutral )

-0.65
( weak negative )

Syros Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$9.94M
Gross Profit:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2023
Revenue:	$9.94M
Gross Profit:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2022
Revenue:	$14.88M
Gross Profit:	$11.91M (80.06 %)
EPS:	$-3.90

FY	2021
Revenue:	$23.49M
Gross Profit:	$23.49M (100.00 %)
EPS:	$-18.80

Financial Reports:

No articles found.

Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.